Literature DB >> 3078275

Effects of antihypertensive drugs on cardiovascular risk factors.

L G Howes1, W J Louis.   

Abstract

1. Large scale studies have failed to show a substantial benefit of antihypertensive therapy on the incidence of ischaemic heart disease. 2. This may be due to adverse effects of antihypertensive drugs on plasma lipoproteins or because of failure to adequately manage other risk factors for atherogenesis. 3. Hypercholesterolaemia is very common in patients receiving antihypertensive therapy, and is difficult to manage successfully using existing treatment strategies. 4. The achievement of a reduction in mortality and morbidity from ischaemic heart disease amongst hypertensive patients represents a major challenge. Success will probably depend upon the development of adequate methods of lowering plasma cholesterol levels.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3078275     DOI: 10.1111/j.1440-1681.1988.tb01062.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  4 in total

1.  The effects of a single dose of dilevalol on [3H]-noradrenaline plasma kinetics and plasma lipoprotein cholesterol concentrations.

Authors:  L G Howes; P R Rowe; H Krum; W J Louis
Journal:  Br J Clin Pharmacol       Date:  1990-03       Impact factor: 4.335

2.  Pharmacology of celiprolol.

Authors:  W J Louis; O H Drummer; L H Tung
Journal:  Cardiovasc Drugs Ther       Date:  1991-01       Impact factor: 3.727

3.  A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients.

Authors:  R J Milne; S Vander Hoorn; R T Jackson
Journal:  Pharmacoeconomics       Date:  1997-09       Impact factor: 4.981

Review 4.  A risk-benefit assessment of carvedilol in the treatment of cardiovascular disorders.

Authors:  W J Louis; H Krum; E L Conway
Journal:  Drug Saf       Date:  1994-08       Impact factor: 5.606

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.